Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 511

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 3
Chunk 511
---
89,068,332  $6,073  $(81,869,902) $7,204,504 Common stock issued for cash, net of funding costs  -   -   -   -   3,221   1   6,483,392   -   -   6,483,393 Common stock issued for warrant exercise  -   -   -   -   905   -   1,014,859   -   -   1,014,859 Warrants issued for cash, net of funding costs  -   -   -   -   -   -   20,053   -   -   20,053 Fair value of vested stock options  -   -   -   -   -   -   996,430   -   -   996,430 Stock payable towards preference dividend  -   -   -   -   -   -   840   (840)  -   - Net loss  -   -   -   -   -   -   -   -   (10,060,250)  (10,060,250)Balance as of December 31, 2023   141.397  $1   -  $-   5,937  $1  $97,583,906  $5,233  $(91,930,152) $5,658,989 

Year Ended December 31, 2024  Series A Convertible  Series B Convertible             Total    Preferred Stock  Preferred Stock  Common stock  Additional    Accumulated  Stockholders’   Shares   Amount  Shares   Amount  Shares   Amount  Paid in Capital  Stock Payable  Deficit  Equity Balance as of December 31, 2023   141.397  $1   -  $-   5,937  $1  $97,583,906  $5,233  $(91,930,152) $5,658,